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Abstract: 
Altered glutamate signaling contributes to a myriad of neural disorders, 
including schizophrenia. While synaptic levels are intensely studied, 
nonvesicular release mechanisms, including cystine-glutamate exchange, 
maintain high steady-state glutamate levels in the extrasynaptic space. The 
existence of extrasynaptic receptors, including metabotropic group II 
glutamate receptors (mGluR), pose nonvesicular release mechanisms as 
unrecognized targets capable of contributing to pathological glutamate 
signaling. We tested the hypothesis that activation of cystine-glutamate 
antiporters using the cysteine prodrug N-acetylcysteine would blunt 
psychotomimetic effects in the rodent phencyclidine (PCP) model of 
schizophrenia. First, we demonstrate that PCP elevates extracellular 
glutamate in the prefrontal cortex; an effect that is blocked by N-
acetylcysteine pretreatment. To determine the relevance of the above finding, 
we assessed social interaction and found that N-acetylcysteine reverses social 
withdrawal produced by repeated PCP. In a separate paradigm, acute PCP 
resulted in working memory deficits assessed using a discrete trial T-maze 
task, and this effect was also reversed by N-acetylcysteine pretreatment. The 
capacity of N-acetylcysteine to restore working memory was blocked by 
infusion of the cystine-glutamate antiporter inhibitor (S)-4-
carboxyphenylglycine into the prefrontal cortex or systemic administration of 
the group II mGluR antagonist LY341495 indicating that the effects of N-
acetylcysteine requires cystine-glutamate exchange and group II mGluR 
activation. Lastly, protein levels from post mortem tissue obtained from 
schizophrenic patients revealed significant changes in the level of xCT, the 
active subunit for cystine-glutamate exchange, in the dorsolateral prefrontal 
cortex. These data advance cystine-glutamate antiporters as novel targets 
capable of reversing the psychotomimetic effects of PCP. 
Keywords: extrasynaptic, system Xc-, prefrontal cortex, nonvesicular, 
working memory, xCT. 
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Introduction 
Abnormal signaling in the prefrontal cortex has been proposed 
to contribute to schizophrenia (Weinberger, 1987; Bunney and 
Bunney, 2000; Chavez-Noriega et al., 2002), however, the precise role 
of glutamate is equivocal since evidence indicates that either an 
increase or a decrease in glutamate signaling may contribute to the 
symptoms of the disease. A hypoglutamatergic state is supported by 
functional imaging studies revealing diminished activation of the 
frontal cortex in schizophrenics (Barch et al., 2001; MacDonald et al., 
2005). Further, noncompetitive NMDA receptor antagonists, including 
phencyclidine (PCP), exacerbate symptoms in schizophrenic patients 
and produce a broad range of schizophrenia-like symptoms in humans 
and rats (Luby et al., 1959; Pearlson, 1981; Javitt and Zukin, 1991; 
Krystal et al., 1994; Malhotra et al., 1997); thus, hypoglutamatergic 
function through NMDA receptors is sufficient to produce a 
schizophrenia-like state. In contrast, a hyperglutamatergic hypothesis 
stems from evidence that noncompetitive NMDA receptor antagonists 
increase extracellular glutamate levels in the prefrontal cortex which 
generates an increase in the firing rate of cortical neurons 
(Moghaddam and Adams, 1998; Lorrain et al., 2003; Jackson et al., 
2004), and that these changes are necessary for the psychotomimetic 
effects of PCP (Moghaddam and Adams, 1998; Homayoun et al., 
2005). 
The uncertainty regarding glutamate dysfunction and 
schizophrenia may arise, in part, by the existence of multiple, distinct 
pools of glutamate that are present in the synaptic and extrasynaptic 
spaces. Continuous nonvesicular glutamate release has been detected 
following NMDA receptor activation, but only after sodium-dependent 
glutamate transporters were blocked (Jabaudon et al., 1999). This 
finding indicates that nonvesicular glutamate is released into the 
extrasynaptic compartment, but that sodium-dependent transporters 
block entry into the synapse. In support microdialysis experiments 
have repeatedly indicated the existence of extrasynaptic glutamate 
maintained in the microM range by nonvesicular release mechanisms 
(Herrera-Marschitz et al., 1996; Timmerman and Westerink, 1997; 
Baker et al., 2002). The distribution of glutamate receptors outside the 
synapse poses extrasynaptic glutamate as a novel mechanism capable 
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of modulating glutamate signaling in the normal and pathological 
state. 
Cystine-glutamate antiporters represent a mechanism capable 
of nonvesicular glutamate release into the extrasynaptic compartment 
following the exchange of extracellular cystine for intracellular 
glutamate (Baker et al., 2002; Moran et al., 2005{Melendez, 2005 
#15). Studies utilizing microdialysis in the nucleus accumbens or 
electrophysiological recordings from acute prefrontal cortical or 
nucleus accumbens tissue slices indicate that nonvesicular glutamate 
release from cystine-glutamate exchange stimulates extrasynaptic 
group II metabotropic glutamate receptors (mGluR) (Baker et al., 
2002; Xi et al., 2002a; Moran et al., 2005). Because group II mGluRs 
function as autoreceptors (Baskys and Malenka, 1991; Cochilla and 
Alford, 1998; Hu et al., 1999b; Schoepp, 2001; Valenti et al., 2002; Xi 
et al., 2002b), extrasynaptic glutamate maintained by cystine-
glutamate exchange negatively modulates synaptic release of 
glutamate (Moran et al., 2005). Since most studies focus on synaptic 
content, the failure to account for the presence of high, steady-state 
levels of glutamate in the extrasynaptic space represents a critical gap 
in attempts to model the contribution of excitatory neurotransmission 
to brain functioning in both the normal and diseased states. 
Extant data indicate that cystine-glutamate exchange may be 
altered in schizophrenic patients. An increase in the expression of 
group II mGluR has been linked to schizophrenia (Gupta et al., 2005), 
and this could arise in response to chronic understimulation of the 
receptor. Further, schizophrenics exhibit reduced glutathione levels in 
the prefrontal cortex (Do et al., 2000). This may reflect blunted 
cystine-glutamate exchange because cystine uptake into the cell 
represents the rate-limiting step in glutathione synthesis (Bannai, 
1984; Meister, 1991; Sies, 1999). Alternatively, this could lead to 
blunted cystine-glutamate exchange because extracellular glutathione 
metabolism serves as a reservoir for cystine that is critical in 
maintaining cystine-glutamate exchange (Deneke and Fanburg, 1989; 
Sato et al., 1999; Sies, 1999; Kim et al., 2001; Shih et al., 2006). 
Collectively, these data would be expected following a reduction in 
cystine-glutathione activity. 
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To determine whether cystine-glutamate antiporters represent a 
novel target in the treatment of schizophrenia, we examined the 
impact of the cyst(e)ine prodrug N-acetylcysteine on the 
psychotomimetic effects of PCP in rodents. N-acetylcysteine-induced 
changes in the psychotomimetic effects of PCP are hypothesized to 
involve cystine-glutamate exchange and increased signaling through 
group II mGluRs, thus, the effects of N-acetylcysteine were also 
determined in the presence of the cystine-glutamate antiporter 
inhibitor (S)-4-carboxyphenylglycine (CPG) and the group II mGluR 
antagonist LY 341495. Because PCP may produce psychotomimetic 
effects through mechanisms distinct from schizophrenia, we sought to 
better link the present studies to schizophrenia by measuring the 
levels of xCT, the active subunit for cystine-glutamate exchange, in 
post mortem tissue obtained from schizophrenic patients. Collectively, 
these experiments may establish cystine-glutamate exchange as a 
novel mechanism capable of contributing to the psychotomimetic 
effects of PCP and possibly schizophrenia. 
Materials and Methods 
Animals and Surgeries 
Male Sprague Dawley rats (Harlan, Indianapolis, IN) weighing 
300–350 g were individually housed in a temperature-controlled 
colony room with a 12-h light/dark cycle with food and water available 
ad libitum. The housing conditions and care of the rats was in 
accordance with the Animal Welfare Act, and all procedures were 
approved by the Marquette University IACU Committee. Rats included 
in the microdialysis studies were anesthetized using pentobarbital (50 
mg/kg, IP) with atropine sulfate (1 mg/kg, IP) pretreatment to limit 
tracheobronchial secretions. Bilateral guide cannula (20 gauge, 14 
mm; Plastics One, Roanoke VA) were implanted using coordinates (+ 
3.1 mm anterior and + 1.0 mm mediolateral to Bregma, and −0.75 
mm ventral from the surface of the skull at a 6° angle from vertical) 
derived from Paxinos and Watson (1986). Rats were then given at 
least five days to recover from surgery prior to testing. 
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Drug Treatments 
(S)-4-Carboxyphenylglycine (CPG; Tocris-Cooksin, Ellisville, MO) 
pretreatment, when used, was infused into the prefrontal cortex via 
reverse dialysis for 180 min prior to behavioral testing. N-
acetylcysteine (Sigma, St. Louis, MO) pretreatments occurred 90 or 
100 min prior to PCP administration in behavioral and microdialysis 
experiments, respectively. LY341495 (Tocris-Cookson, Ellisville, MO) 
pretreatments occurred 70 min prior to PCP administration. 
Phencyclidine (PCP; NIDA Drug Supply Program, Research Triangle, 
NC) was administered 60 min prior to commencement of behavioral 
testing. Drug treatments in the microdialysis and t-maze studies 
involved acute administration; treatments in the social interaction 
experiments involved administration over 14 consecutive days. 
In vivo Microdialysis 
Microdialysis experiments were conducted as previously 
described (Baker et al., 2002). Briefly, removable probes were 
inserted through the guide cannulae into the prefrontal cortex. The 
next day, dialysis buffer (5 mM glucose, 140 mM NaCl, 1.4 mM CaCl2, 
1.2 mM MgCl2, and 0.15% phosphate buffer saline, pH 7.4) was 
pumped through the probes at 2 μl/min for at least 3 hr; afterwards 
20 min samples were collected before and after drug treatments as 
described above. Glutamate concentrations in the samples were 
determined using HPLC coupled to fluorescence detection as reported 
previously (Baker et al., 2002). Reverse dialysis was conducted as 
described above except the buffer also contained CPG (1 μM) and the 
flow rate was 1 μl/min. 
T-Maze Paradigm 
Access to food was restricted to 15 g of rat chow/day during t-
maze training and testing. Rats were trained until accuracy in a 
choice-alternation t-maze task exceeded 80% over three days. Daily 
sessions involved 10 trials per day with each trial consisting of a 
restricted and an unrestricted run. In the restricted run, a randomly 
determined arm was baited with cereal and the opposite arm was 
blocked. Ten seconds later, the unrestricted run was conducted 
whereby the rat had access to both arms of the maze but cereal was 
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placed only in the arm blocked during the preceding restricted run. A 
correct choice occurred when the rat entered the baited arm during 
the unrestricted run. Training continued until performance exceeded 
80% for at least three days. 
Social Interaction 
Social interaction was measured as described by Sams-Dodd 
(1999). Briefly, interaction was measured in rats that had received 
fourteen daily administrations of N-acetylcysteine (0–90 mg/kg, IP) 
followed by PCP (0–3 mg/kg, SC). On day 14, unfamiliar rat pairs 
receiving identical drug treatments were placed into an open-field 
maze (150 × 100 × 40 cm) and the amount of time spent within 20 
cm was measured. The predictive validity of this procedure as a 
negative model of schizophrenia has previously been established 
(Sams-Dodd, 1999). 
Brain Tissue preparation 
Postmortem brain tissue from elderly, well diagnosed patients 
with schizophrenia and a comparison group was obtained from the 
Mount Sinai Medical Center Brain Bank (Table 1). Subjects were 
matched for age, postmortem interval (PMI) and pH, and did not show 
any signs of neurodegenerative disorders or other discernable 
neuropathologies, including Alzheimer’s disease (Purohit et al., 1998). 
Patients with a medication history had only been treated using typical 
antipsychotic medications. Tissue blocks containing dorsolateral 
prefrontal cortex (DLPFC), anterior cingulate cortex (ACC) and 
hippocampus were dissected from coronal sections, snap frozen and 
kept at −80°C until further processing. Approximately 1 cm3 of tissue 
from each region was grinded on dry ice and subsequently 
homogenized (10% W/V) in ice-cold 50 mM Tris-HCl (pH 7.0) for 30 
sec with a polytron homogenizer and stored at −80°C. Protein 
concentration of tissue homogenates was determined by the Bradford 
method (Bradford et al., 1987). 
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PMI = postmortem interval; N = number of subjects in the study; F = female; M = 
male; Rx<6wk = on antipsychotic medication within 6 weeks of death (only typical 
neuroleptics); COPD = Chronic obstructive pulmonary disease; N.I.D.D. = non-insulin 
dependent diabetes; A.S.H.D. = arteriosclerotic heart disease; CHF = Congestive 
Heart Failure. 
Western blotting: Human Brain Tissue 
Tissue homogenates from each subject (25 μg per lane) were 
mixed with 6x sample buffer (4.5% sodium dodecyl sulfate, 170 mM 
Tris-HCl (pH 6.8), 36% glycerol, 15% β-mercaptoethanol, 0.018% 
bromophenol blue) and heated at 95°C for 4 minutes. Samples were 
loaded in duplicate onto 10% SDS-PAGE (Bio-Rad Laboratories, Inc) 
and separated at 100 volts in electrophoresis buffer (25 mM Tris-base, 
192 mM glycine, 0.1% SDS). After overnight transblotting (Trans-Blot 
Cell, Bio-rad Laboratories, Inc), protein-containing nitrocellulose 
membranes were blocked with 5% non-fat dry milk solution for one 
hour at room temperature and washed with TBS buffer containing 0.1 
% Tween 20 (TBS-T). The blots were subsequently incubated with 
rabbit-anti-xCT antibody (TransGenic Inc., Japan; see figure 7) 
overnight at 4° C. Blots were washed with TBS-T (3X) for 5 min and 
incubated with HRP-conjugated secondary antibody (1hr). After 
washing (3X) in TBS-T buffer, the signal was detected with enhanced 
chemiluminescent substrate (Amersham Biosciences). Membranes 
were then stripped for 30 minutes at 55°C (62.5mM Tris-Cl (pH 6.7), 
2% SDS, 100 mM β-mercaptoethanol), washed thoroughly in dH2O 
and blocked in phosphate buffered saline (PBS) containing 3% dry 
milk. Blots were again incubated overnight with mouse anti-β-tubulin 
antibody (Upstate Biotechnology), washed briefly, and incubated with 
horseradish peroxidase-coupled secondary antibody (1hr; Upstate 
Biotechnology) and developed using enhanced chemiluminescence. 
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Figure 7 Knockdown or overexpression of xCT altered xCT RNA or protein levels as 
determined using semi-quantitative multi-plex RT-PCR (a), western blotting (b), and 
immunofluorescence (c). (a) The expression of hxCT RNA (724 bp) was equivalent 
between mock and control siRNA transfected cells. Cells transfected with hxCT siRNA 
(empty vector) exhibited a >90% reduction of hxCT transcript relative to mock 
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controls. Cells co-transfected with mouse xCT (mxCT) cDNA plus hxCT siRNA 
expressed an increase in mxCT (182 bp) and a reduction in hxCT. The expression of 
the internal control, 18S rRNA, was equivalent or higher across all cells relative to 
mock controls. (b) The expression of xCT protein (55kD) was equivalent between 
mock and control siRNA transfected cells. Cells transfected with siRNA (+ empty 
vector) exhibited an 80% reduction of hxCT relative to mock controls. Transfection of 
cDNA mxCT restored xCT protein. β-actin levels were unchanged across all 
transfection conditions. (c) xCT labeling was evident in the mock and control siRNA 
transfected cells. Depletion of xCT labeling was observed in hxCT siRNA (+ empty 
vector) transfected cells. Transfection with mxCT cDNA along with hxCT siRNA 
restored xCT labeling. Collectively, these results demonstrated antibody specificity 
against the xCT protein for both human and mouse species. 
Knockdown and overexpression of xCT in HEK cells 
Approximately 50000 cells were split into a six-well plate. These 
studies utilized a siRNA duplex of human xCT 
[5′AAATGCCCAGATATGCATCGT-3′ (SLC7A11_1237)] which targets 
nucleotides 1237–1257 of the SLC7A11 mRNA sequence of 
NM_014331 and has previously been used to knockdown human xCT 
(hxCT) (Huang et al., 2005). HEK 293 cells were transfected with 
approximately 20 nM of siRNA using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA); the transfection efficiency exceeded 80% in all the 
experiments. The effect of RNAi was evaluated by multiplex RT-PCR, 
western blot, and immunofluorescence (see figure 7). In some cells, 
mouse xCT (mxCT) was overexpressed by cotransfection of 2 μg 
pCDNA3-xCT plasmid with hxCT siRNA; control cells received an 
equivalent amount of empty vector co-transfected with siRNA. Mock 
cells were incubated (48h) in Lipofectamine 2000 only. Additional cells 
were also incubated with a negative control siRNA (Ambion, Austin, 
Texas). 
Semi-quantitative multiplex RT-PCR 
After transfection (48 h), total RNA was isolated by Trizol 
(Invitrogen) reagent and approximately 100 ng of total RNA was used 
for RT. The first strand of cDNA was synthesized by Superscript 
Reverse Transcriptase (Invitrogen). The RT-product was amplified by 
PCR using appropriate gene-specific primers and a primer for 18S 
rRNA (Ambion Inc, TX) which served as an internal control in the same 
reaction (see figure 7). The conditions used to amplify the PCR 
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products were 94° C for 40 seconds, 58° C for 45 seconds, and 72° C 
for 45 seconds for 30 cycles, and then 72° C for 7 min extension. 
Western blotting: HEK 293 Cells 
Transfected cells were washed with ice-cold PBS and lysed (10 
mM Na2 PO4 pH 7.4, 150 mM NaCl, 5 mM EDTA, 5 mM EGTA, 1% 
Triton X-100, cock-tail protease inhibitor (Roche Biochemicals) and 1 
mM PMSF). Protein concentration was determined using the BCA 
assay; protein (30 μg) was loaded onto 10% SDS-PAGE gels. Resolved 
proteins were transferred onto PVDF membrane and blocked with 5% 
non-fat dry milk solution (1hr). Blots were subsequently incubated 
with primary antibody against mouse xCT (figure 7) overnight at 4° C 
and then with HRP-conjugated secondary antibody (1hr). The signal 
was detected by enhanced chemiluminesence (Pierce Biotechnology 
Inc, IL). Blots were stripped (SignaGen, MD) and re-probed with β-
actin antibody (Santacruz biotechnology Inc. CA). 
Immunofluorescence analysis 
Transfected cells were subjected to immunofluorescence 
analysis. Cells were grown on poly L-lysine coated cover slips and fixed 
with 4% paraformaldehyde in PBS for 10 min. Cells were washed with 
PBS (3X), permeabilized with 0.1% Triton X-100 for 10 min, washed 
again with PBS (3X) and blocked with 5% normal donkey serum. Cells 
were then labeled with xCT primary antibody (see figure 7) with a 
dilution of 1:10 overnight at 4°C. After washing with PBS (3X) cells 
were incubated with Cy-3 conjugated secondary antibody (Jackson 
Immunoresearch, PA) for one hour at room temperature and washed 
with PBS for (2–3X). Finally, cover slips were mounted in ProLong Gold 
antifade medium (Invitrogen) and cells were examined using a 
confocal microscope (Zeiss). 
Histology 
Tissue slices obtained from rats included in the microdialysis 
studies were stained with cresyl violet to verify probe placements. 
Three rats determined to have misplaced guide cannula were excluded 
from all analyses. 
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Statistics 
Microdialysis and behavioral data were analyzed using analysis 
of variance (ANOVA) with drug treatment as a between subject factor 
and sample number as a repeated factor (microdialysis). Significant 
main effects and interactions were further evaluated using Tukey HSD. 
Measures of post mortem xCT were initially analyzed using multiple 
regression to exclude effects caused by age, PMI and pH. Analysis of 
covariance was utilized when significant associations were obtained 
between xCT expression and the above independent variables; 
univariate ANOVA was used in the absence of a significant association. 
For all tests α = 0.05. 
Results 
N-acetylcysteine blocks PCP-evoked glutamate release 
in the prefrontal cortex 
The psychotomimetic effects of PCP are dependent upon 
elevated glutamate in the prefrontal cortex (Moghaddam and Adams, 
1998). As a result, we examined the impact of N-acetylcysteine 
pretreatment on the neurochemical effects of PCP. Similar to earlier 
findings, figure 1 illustrates that systemic administration of PCP 
produces a dose-dependent increase in extracellular glutamate levels 
in the prefrontal cortex. Rats pretreated with N-acetylcysteine (90 
mg/kg, IP) failed to exhibit this increase indicating that N-
acetylcysteine blocked PCP-induced glutamate. Basal levels of 
glutamate did not differ between rats receiving 3 mg/kg PCP with or 
without N-acetylcysteine (mean ± SEM: 4.2 ± 1, 3.2 ± 0.8 pmole/μL, 
respectively) or 1 mg/kg PCP (mean ± SEM: 3.7 ± 0.8 pmole/μL). The 
region of the prefrontal cortex (figure 2) sampled in this study was 
selected because it corresponds to the human dorsolateral prefrontal 
cortex (Uylings et al., 2003) which has been implicated in 
schizophrenia. 
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Figure 1 N-acetylcysteine (NAC) prevents phencyclidine-evoked glutamate release 
in the rodent prefrontal cortex. Extracellular glutamate in the prefrontal cortex is 
depicted as change from baseline across 20 min samples. (a) A low dose of 
phencyclidine (PCP; 1 mg/kg, SC, N=8) failed to alter extracellular glutamate levels in 
the prefrontal cortex. (b) Rats injected with saline followed by PCP (3 mg/kg, SC; 
n=13) exhibited an increase in extracellular glutamate that was not observed in rats 
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pretreated with N-acetylcysteine (90 mg/kg, IP; n = 13). ANOVA yielded an 
interaction between time and NAC treatment (F15,360=1.74, P=.04) such that there was 
a main effect of time in rats pretreated with saline (0 mg/kg NAC; F15,180=1.97, P=.02) 
but not NAC (90 mg/kg; F15,180=0.87, P=0.596). (c) Extracellular glutamate levels in 
the prefrontal cortex expressed as mean (± SEM) area under the curve (AUC) 
following the PCP injection; ANOVA yielded a main effect of treatment (F1,24 = 4.86, P 
= 0.037); * indicates an increase in AUC in rats pretreated with NAC relative to saline 
pretreated rats, Tukey HSD, p<.05. 
 
Figure 2 A representative coronal section illustrating the placement of 
microdialysis probes within the prefrontal cortex. The tract created by the insertion of 
a microdialysis probe is evident by the tissue damage on the medial aspect of each 
hemisphere. Note, the left hemisphere of each coronal section is marked with a tissue 
punch, which is evident as a cavity in the right side of the above, inverted section. 
N-acetylcysteine attenuates PCP-evoked performance 
deficits in a t-maze task 
Working memory deficits linked to schizophrenia have been 
modeled by measuring PCP-induced deficits in rats (Moghaddam and 
Adams, 1998; Krystal et al., 2003; Harvey and McClure, 2006). This 
paradigm has predictive validity in that cognitive deficits associated 
with schizophrenia and working memory deficits produced by 
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noncompetitive NMDA receptor antagonists are at least partially 
responsive to clozapine (Faltus et al., 1973; Hauber, 1993; Breier et 
al., 1994). Figure 3a illustrates that PCP dose-dependently reduced 
performance in a t-maze task. Acute administration of the lowest dose 
(1 mg/kg, SC) of PCP failed to reduce performance while the highest 
dose (3 mg/kg, SC) produced the maximal attainable deficit since 50% 
accuracy represents chance performance. Interestingly, the low dose 
also failed to increase glutamate levels in the prefrontal cortex. N-
acetylcysteine (90 mg/kg, IP) administered alone did not alter 
performance in a t-maze task (figure 3b). However, rats receiving N-
acetylcysteine (90 mg/kg, IP) prior to PCP administration exhibited 
significantly higher accuracy than rats treated with PCP alone 
indicating that N-acetylcysteine attenuated PCP-induced t-maze 
deficits (figure 3b). 
 
Figure 3 N-acetylcysteine (NAC) blocks PCP-evoked t-maze deficits. (a) Mean (± 
SEM) accuracy in a discrete-trial T-maze task following an injection of PCP (0–3 
mg/kg, SC; n = 4–13/group as indicated in the bars of the graph). Pretreatment (60 
min) with PCP (1–3 mg/kg, SC) dose-dependently produced working memory deficits 
evident as a decrease in the percent of correct choices during ten daily trials; ANOVA 
yielded a main effect of treatment (F3,33 = 41.99, P < 0.001). * indicates a difference 
from controls, Tukey HSD, p<.05. (b) Mean (± SEM) accuracy in a discrete-trial T-
maze task in rats pretreated (90 min) with NAC (90 mg/kg, IP; n = 7–29/group) prior 
to PCP (0–3 mg/kg, SC). NAC administration reverses PCP-induced working memory 
deficits; ANOVA yielded a main effect of treatment (F5,92 = 25.5, P < 0.001). * 
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indicates a difference relative to rats receiving saline alone (sal + 0 PCP), Tukey HSD, 
p<.05. # indicates a difference relative to rats receiving saline and respective dose of 
PCP, Tukey HSD, p<.05. 
N-acetylcysteine is used to target cystine-glutamate antiporters 
because it is a prodrug for cyst(e)ine (Williamson and Meister, 1981; 
Meister, 1985; Pileblad and Magnusson, 1992). However, cysteine can 
also be transported by the sodium-dependent glutamate transporter 
EAAC1 (Aoyama et al., 2006). To distinguish between these two 
mechanisms, we examined the capacity of the cystine-glutamate 
antiporter inhibitor CPG to block the effects of N-acetylcysteine (figure 
4a). Infusion of CPG into the prefrontal cortex had no effect when 
administered alone or with PCP. However, rats receiving CPG along 
with N-acetylcysteine and PCP exhibited a significant reduction in 
performance relative to a drug-free (sham) session. In contrast, rats 
treated with N-acetylcysteine and PCP only did not exhibit a deficit in 
performance. Collectively, these data are consistent with the 
hypothesis that N-acetylcysteine targets cystine-glutamate antiporters 
in the prefrontal cortex to restore working memory. 
 
Figure 4 The capacity of N-acetylcysteine (NAC) to reverse PCP-evoked t-maze 
deficits is blocked by inhibitors of cystine-glutamate exchange and group II mGluRs. 
(a) Mean (± SEM) accuracy in a discrete-trial T-maze task assessed during a drug-
free session (sham) and a test day in which the cystine-glutamate antiporter inhibitor 
(S)-4-carboxyphenylglycine (CPG; 1 μM) was infused into the dorsolateral prefrontal 
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cortex for 180 min before testing. Rats also received a systemic injection of N-
acetylcysteine (0 or 90 mg/kg, IP; 160 min prior to testing) and phencyclidine (PCP; 0 
or 2 mg/kg, SC; 60 min prior to testing) on the test day. Rats treated with PCP alone 
exhibited a deficit in working memory evident as a reduction in t-maze performance 
on the test day relative to the sham day (PCP, 2 mg/kg, SC; n = 4); this deficit was 
reversed by co-administration of N-acetylcysteine (90 mg/kg, IP; n = 5). Rats 
receiving CPG + N-acetylcysteine + PCP (n = 6) exhibited deficits in performance 
comparable to rats receiving only PCP or PCP + CPG (n = 6). ANOVA yielded a day x 
treatment interaction (F5,25 = 5.235, P = .002). * indicates a difference relative to 
performance on respective sham day (T-test, P<.05). (b) Mean (± SEM) accuracy in a 
discrete-trial T-maze task in rats pretreated with NAC (90 mg/kg, IP; 90 min) and the 
group II mGluR antagonist LY341495 (1 mg/kg, IP; 70 min) prior to PCP (2 mg/kg, 
SC; n = 7–16/group). PCP produced a reduction in t-maze performance evident as a 
decrease in the percent of correct choices during ten daily trials, and this deficit was 
reversed by NAC pretreatment. Rats receiving NAC + LY341495 prior to PCP exhibited 
deficits in performance comparable to rats receiving PCP alone; ANOVA yielded a main 
effect of treatment (F4,47 = 14.42, P < 0.001). * indicates a difference relative to 
vehicle controls, Tukey HSD, p<.05; # indicates a difference from rats treated with 
PCP + NAC, Tukey HSD, p<.05. 
Previous work indicates that cystine-glutamate antiporters 
regulate synaptic glutamate through activation of group II mGluRs 
(Baker et al., 2002; Moran et al., 2005). As a result, we examined 
whether the capacity of N-acetylcysteine to restore working memory 
requires group II mGluR signaling. Figure 4b illustrates that 
pretreatment with the group II mGluR antagonist LY341495 did not 
alter PCP-induced deficits in working memory. Rats pretreated with 
both N-acetylcysteine (90 mg/kg, IP) and LY341495 (1 mg/kg, IP) 
prior to PCP (2 mg/kg, SC) administration exhibited deficits in 
performance comparable to rats receiving PCP alone. This finding 
indicates that N-acetylcysteine blocks the capacity of acute PCP 
treatment to produce working memory deficits through a group II 
mGluR dependent mechanism. 
N-acetylcysteine attenuates PCP-evoked social 
withdrawal 
The impact of N-acetylcysteine on social withdrawal produced by 
repeated PCP treatment was assessed because this task has been used 
to model the negative symptoms of schizophrenia (Sams-Dodd, 1999). 
Similar to t-maze performance, this paradigm has predictive validity in 
that negative symptoms linked to schizophrenia or repeated PCP-
induced behavioral deficits that are used to model these symptoms are 
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at least partially responsive to clozapine (Breier et al., 1994; Corbett 
et al., 1995; Sams-Dodd, 1999). Social withdrawal was evident as a 
reduction in the amount of time that two unfamiliar rats spent in close 
proximity when treated with PCP (3 mg/kg, SC) relative to saline 
(figure 5). Rats pretreated with N-acetylcysteine prior to PCP 
administration spent a comparable amount of time within close 
proximity as saline controls, indicating that N-acetylcysteine 
administration blocked PCP-evoked social withdrawal. Similar to t-
maze performance, administration of LY341495 blocked the effects of 
N-acetylcysteine indicating that group II mGluR activation is necessary 
for social interaction restored by N-acetylcysteine (figure 5). 
 
Figure 5 N-acetylcysteine (NAC) blocks PCP-evoked social withdrawal in a group II 
mGluR-dependent manner. Social interaction was assessed as the mean (± SEM) time 
unfamiliar rat pairs spent within 20 cm. PCP (3 mg/kg, SC; n = 6–14) produced a 
decrease in interaction time and this effect that was reversed by NAC (90 mg/kg, IP) 
pretreatment (90 min). LY341495 (1 mg/kg, IP) reversed the protective effects of NAC 
indicating a role for mGluR II receptors in the effects of NAC; ANOVA yielded a main 
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effect of treatment (F3,34 = 5.217, P = 0.005). * indicates a difference relative to 
vehicle controls, Tukey HSD, p<.05; # indicates a difference relative to rats treated 
with NAC + PCP, Tukey HSD, p<.05. 
Protein levels of xCT are altered in schizophrenic post 
mortem tissue 
Post mortem tissue levels of xCT, the active subunit for cystine-
glutamate antiporters, were measured in the human dorsolateral 
prefrontal cortex (DLPFC), anterior cingulate cortex (ACC) and 
hippocampus (HPC). Correlation analysis including age, pH, and PMI 
was performed for xCT expression in all regions. A positive correlation 
between xCT expression was identified for pH in DLPFC (r=0.30, 
P=0.036). For all other regions, correlation analysis was not significant 
for any of the variables tested. Figure 6 illustrates that tissue obtained 
from schizophrenic patients had higher xCT protein levels in the DLPFC 
relative to controls, without significant changes in ACC and HPC. Note, 
there was no significant effect of gender or medication history on xCT 
expression in DLPFC. In support of the latter, xCT protein levels in the 
DLPFC did not differ between patients treated within 6 weeks of death 
and unmedicated individuals (see figure 6c). This indicates that typical 
antipsychotics do not exert therapeutic effects by altering xCT levels. 
Figure 7 illustrates the specificity of the anti-xCT antibody used in the 
above study. Specifically HEK cells treated with xCT siRNA displayed a 
reduction in xCT RNA and protein. An increase in xCT RNA and protein 
was detected in HEK cells transfected with xCT cDNA (figure 7). 
Collectively, these studies provide the first measures of xCT in 
schizophrenic patients, and further support extant data that is 
consistent with a reduction of cystine-glutamate exchange in 
schizophrenia. 
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Figure 6 Protein expression of xCT is significantly higher in the dorsal lateral 
prefrontal cortex (DLPFC) of schizophrenic patients. (a) Levels of the catalytic subunit 
for cystine-glutamate antiporters, xCT protein, are expressed as a change (mean ± 
SEM) from controls (n = 27) in the ratio of xCT/β-tubulin measured from human 
DLPFC (n = 23; ANCOVA: F1,45 = 5.6, P = 0.022), anterior cingulate cortex (ACC; n = 
23; ANCOVA: F1,45 = 0.03, P = 0.870), and hippocampus (n = 23; ANCOVA: F1,45 = 
0.69, P = 0.41). * indicates a difference from control tissue, p<.05. (b) 
Representative immunoblots illustrate bands with an apparent molecular mass of 55 
kDa. (c) The mean (± SEM) levels of xCT in patients that received antipsychotic 
therapy within the last six weeks (n = 12) relative to those that had not (n = 10). 
Discussion 
As the primary excitatory neurotransmitter in the brain, 
glutamate is involved in most aspects of neurotransmission in the 
normal and diseased states. The complexity of glutamate signaling has 
begun to emerge over the past decade with discoveries detailing the 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Neuropsychopharmacology, Vol. 33, No. 7 (June 2008): pg. 1760-1772. DOI. This article is © Nature Publishing Group 
(Macmillan Publishers Limited) and permission has been granted for this version to appear in e-Publications@Marquette. 
Nature Publishing Group (Macmillan Publishers Limited) does not grant permission for this article to be further 
copied/distributed or hosted elsewhere without the express permission from Nature Publishing Group (Macmillan 
Publishers Limited). 
23 
 
existence of vesicular glutamate release from astrocytes and the 
distinction between functional glutamate receptors in extrasynaptic 
and synaptic regions. Unfortunately, a dearth of knowledge exists 
regarding the involvement of extrasynaptic glutamate to 
neurotransmission in the normal or pathological states, despite the 
importance of glutamate signaling to brain function. The primary 
finding of the present report is that cystine-glutamate antiporters, a 
mechanism capable of nonvesicular release (Baker et al., 2002), can 
be targeted to reverse the psychotomimetic effects of acute or 
repeated PCP. The importance of this, coupled with an earlier 
observation that altered cystine-glutamate antiporter activity 
contributes to compulsive cocaine seeking (Baker et al., 2003; Lu et 
al., 2004), is that nonvesicular glutamate release may contribute to 
neural disorders involving glutamate or represent novel targets in the 
development of pharmacotherapies. This conclusion is supported by 
our observation that post mortem tissue obtained from schizophrenic 
patients exhibited altered levels of xCT, the active subunit for cystine-
glutamate antiporters, in the dorsolateral prefrontal cortex. 
N-acetylcysteine reversal of psychotomimetic effects of 
PCP 
The psychotomimetic effects of PCP in rodents require increased 
levels of synaptic glutamate in the rodent prefrontal cortex, 
stimulation of AMPA receptors, and subsequent increased burst firing 
of cortical neurons (Moghaddam et al., 1997; Moghaddam and Adams, 
1998; Homayoun et al., 2005). Not surprisingly, increased levels of 
glutamate and burst firing of cortical neurons are blocked by 
stimulating group II mGluRs (Moghaddam and Adams, 1998; 
Homayoun et al., 2005) since these receptors function as 
autoreceptors on presynaptic glutamatergic terminals (Kilbride et al., 
1998; Schoepp et al., 1999; Marek et al., 2000). Similar to agonists 
for group II mGluR, the present data demonstrate that administration 
of the cysteine prodrug N-acetylcysteine blocks PCP-evoked glutamate 
release in the prefrontal cortex in a manner that requires cystine-
glutamate exchange and increased group II mGluR signaling. This 
finding is consistent with several studies demonstrating that cystine-
glutamate antiporters regulate endogenous stimulation of these 
receptors (Baker et al., 2002; Baker et al., 2003; Moran et al., 2005). 
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These studies reinforce the hypothesis that multiple pools of glutamate 
exist and that extrasynaptic pools provide negative feedback 
regulating synaptic release. 
It may seem paradoxical that targeting cystine-glutamate 
exchange, which increases nonvesicular glutamate, is effective in 
reducing the psychotomimetic effects of PCP since these behaviors 
require increased synaptic glutamate (Moghaddam and Adams, 1998; 
Lorrain et al., 2003; Jackson et al., 2004), however, this may reflect 
the existence of multiple, functionally-distinct pools of glutamate. 
Noncompetitive NMDA receptor antagonists increase glutamate in the 
synaptic cleft thereby generating behaviors dependent upon AMPA 
receptor stimulation (Moghaddam et al., 1997; Takahata and 
Moghaddam, 2003). Conversely, cystine-glutamate exchange releases 
glutamate into the extrasynaptic compartment thereby stimulating 
proximal receptors such as group II mGluRs (Baker et al., 2002; Baker 
et al., 2003; Moran et al., 2005). By stimulating extrasynaptic group II 
mGluRs without exerting postsynaptic effects (Moran et al., 2005), 
extrasynaptic glutamate appears to negatively influence the synaptic 
pools (Baker et al., 2002; Moran et al., 2005). The 
compartmentalization of glutamate is likely the result of sodium-
dependent glutamate transporters. These transporters are active in 
clearing glutamate released from cystine-glutamate exchange (Baker 
et al., 2002) and, prevents glutamate maintained by nonvesicular 
release to access synaptic receptors (Jabaudon et al., 1999). To the 
extent that NR2B receptors are located outside the synapse, this 
hypothesis is supported by the recent observation that glutamate 
release from astrocytes appears to stimulate extrasynaptic, but not 
synaptic NMDA receptors (D’Ascenzo et al., 2007). The existence of 
multiple pools may partially account for the ambiguity regarding the 
contribution of glutamate to schizophrenia in which both increased and 
decreased glutamate signaling have been hypothesized (Moghaddam 
and Adams, 1998; Barch et al., 2001; MacDonald et al., 2005). 
Specifically, decreased cystine-glutamate antiporter activity would lead 
to reduced extrasynaptic glutamate resulting in increased synaptic 
levels of glutamate due to diminished group II mGluR stimulation. 
Regardless, these data further establish cystine-glutamate exchange 
as a novel mechanism capable of regulating glutamate signaling. 
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The psychotomimetic effects of PCP were assessed in the 
present studies by measuring performance deficits in a t-maze task 
dependent upon working memory and social interaction. These 
behaviors were selected, in part, because they model cognitive deficits 
and negative symptoms of schizophrenia, respectively (Moghaddam 
and Adams, 1998; Sams-Dodd, 1999) and these symptoms are not 
adequately treated with existing medications (Lieberman et al., 2005). 
Further, the behavioral deficits in these paradigms are produced by 
acute (t-maze) and repeated (social interaction) administration of PCP, 
both of which have merits as screens for putative antipsychotics. The 
predictive validity of these behavioral deficits in identifying 
antipsychotic efficacy is evident from studies showing that existing 
medications that are at least partially effective in treating cognitive 
deficits and negative symptoms of schizophrenia in humans also 
interfere with these behaviors in rodents (Faltus et al., 1973; Hauber, 
1993; Breier et al., 1994; Corbett et al., 1995; Sams-Dodd, 1999). 
Consistent with earlier findings, these data indicate that PCP produces 
deficits in t-maze performance and social withdrawal (Moghaddam and 
Adams, 1998; Sams-Dodd, 1999). Interestingly, a dose of PCP that 
failed to elevate extracellular glutamate in the prefrontal cortex also 
failed to produce working memory deficits further indicating a 
relationship between increased extracellular glutamate in the 
prefrontal cortex and the psychotomimetic effects of PCP. Moreover, 
N-acetylcysteine, which blocked PCP-induced glutamate overflow, also 
prevented both PCP-induced working memory deficits and social 
withdrawal. The capacity of N-acetylcysteine to reverse the 
psychotomimetic effects of PCP is blocked by inhibitors of cystine-
glutamate exchange and group II mGluRs. These data are consistent 
with the hypothesis that the psychotomimetic effects of PCP arise, in 
part, due to elevated extracellular glutamate levels in the prefrontal 
cortex, and that increased cystine-glutamate exchange represents a 
strategy to reverse behavioral deficits used to model aspects of 
schizophrenia. As a result, cystine-glutamate antiporters may 
represent a novel target in the treatment of schizophrenia. 
Cystine-Glutamate Exchange & Schizophrenia 
Post mortem levels of xCT, the active subunit for cystine-
glutamate exchange, are increased in the dorsolateral prefrontal 
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cortex of human schizophrenic patients. The labeling of xCT in the 
prefrontal cortex is consistent with earlier studies demonstrating 
cystine-glutamate exchange in the rat medial prefrontal cortex (Moran 
et al., 2005), a region thought to be analogous to human dorsolateral 
prefrontal cortex (Uylings et al., 2003). Although the modest change in 
protein levels detected in the present study does not provide direct 
evidence that altered cystine-glutamate exchange occurs in 
schizophrenia, it is consistent with several lines of evidence that 
reinforce this hypothesis. Schizophrenics exhibit reduced glutathione 
levels in the prefrontal cortex (Do et al., 2000). This may reflect 
blunted cystine-glutamate exchange because cystine uptake into the 
cell represents the rate-limiting step in glutathione synthesis (Bannai, 
1984; Meister, 1991; Sies, 1999). Alternatively, this could cause 
blunted cystine-glutamate exchange because extracellular glutathione 
metabolism serves as a reservoir for cystine that is critical in 
maintaining cystine-glutamate exchange (Deneke and Fanburg, 1989; 
Sato et al., 1999; Sies, 1999; Kim et al., 2001; Shih et al., 2006). 
Regardless, either would diminish glutamate release from cystine-
glutamate exchange. In support, earlier work has also detected 
increased levels of mGluR II receptors in post mortem tissue from 
schizophrenic patients (Gupta et al., 2005), which would be expected 
following long-term understimulation of the receptor. Collectively, the 
changes in xCT, glutathione, and group II mGluRs provide indirect 
evidence of reduced cystine-glutamate antiporter activity in 
schizophrenia and should serve to stimulate direct measures of 
cystine-glutamate function in schizophrenia in future experiments. 
Although indirect evidence of altered function, the above data 
are compelling because blunted cystine-glutamate exchange could 
account for a myriad of pathological events thought to underlie 
schizophrenia including increased AMPA receptor stimulation, 
decreased NMDA receptor stimulation, depletion of glutathione, 
increased dopamine release, and abnormal neurodevelopment. As 
noted above, a reduction in glutamate release from cystine-glutamate 
exchange would be expected to decrease stimulation of group II 
mGluRs (Baker et al., 2002; Moran et al., 2005). Diminished activity of 
group II mGluRs would result in augmented synaptic release of 
glutamate and dopamine leading to increased stimulation of 
postsynaptic receptors, including AMPA receptors (Hu et al., 1999a; 
Cartmell and Schoepp, 2000; Baker et al., 2002; Chaki et al., 2006). 
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Despite the increase in synaptic glutamate, NMDA receptor 
hypofunction may arise through at least two mechanisms. First, a 
reduction in extracellular glutathione would decrease NMDA receptor 
sensitivity by decreasing the activation of extracellular redox sites 
(Kohr et al., 1994). Second, metabolism of extracellular glutathione by 
the membrane-bound enzyme gamma-glutamyl transpeptidase 
represents a source of extracellular glycine (Abbott and Meister, 
1986), which is known to function as a coagonist for the NMDA 
receptor. In support, glutathione depletion has been shown to produce 
NMDA receptor hypofunction (Steullet et al., 2006) as well as several 
behavioral abnormalities used to model schizophrenia (Cabungcal et 
al., 2006). 
Diminished cystine-glutamate exchange may also result in 
impaired neurodevelopment. In support, nonvesicular glutamate has 
been shown to be a key regulator of postsynaptic development in 
Drosophila by regulating the expression of postsynaptic glutamate 
receptors during synaptogenesis. Specifically, decreased nonvesicular 
glutamate release resulted in increased expression of postsynaptic 
glutamate receptors (Featherstone et al., 2002); an effect recently 
linked to cystine-glutamate exchange (Augustin et al., 2007). 
Interestingly, postsynaptic glutamate receptor expression influences 
synapse morphology and presynaptic neurotransmitter release in 
Drosophila (Petersen et al., 1997; Sigrist et al., 2000). Nonvesicular 
glutamate release has also been shown to regulate cortical neuron 
migration during neurodevelopment (Manent et al., 2005). Glutamate 
has been previously shown to regulate neuroblast migration by 
functioning to promote migration, and to act as an acceleratory or stop 
signal. Synaptic glutamate is unlikely to contribute to this effect since 
normal cortical development occurs in munc13–1/2 double knock-out 
mice that are incapable of vesicular release of neurotransmitters 
(Verhage et al., 2000). Rather, recent studies indicate that 
nonvesicular release is the source of glutamate involved in neuronal 
development (Manent et al., 2005). Collectively, these data indicate 
that a disruption of nonvesicular release could disrupt cortical 
migration during development, impact synapse formation, and lead to 
altered neurotransmitter release, all of which appear to occur in 
schizophrenia. 
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Given the importance of glutamate and the existence of 
extrasynaptic receptors and release mechanisms, models of brain 
functioning in the normal and diseased states need to account for the 
existence of high, steady state levels of glutamate in the extrasynaptic 
space. The present data reveal that cystine-glutamate exchange 
represents a novel target capable of reversing pathological changes in 
complex, cognitive-dependent behavioral tasks used to model aspects 
of schizophrenia. It is important to note, however, that the 
pathophysiology underlying the psychotomimetic effects of PCP may 
be distinct from those underlying the symptoms of schizophrenia. 
While our data indicating altered xCT expression in postmortem tissue 
obtained from schizophrenic patients is suggestive of a link between 
altered cystine-glutamate exchange and schizophrenia, certainly 
additional data are needed. Moreover, our data, in conjunction with 
earlier work linking diminished cystine-glutamate exchange to 
compulsive drug-seeking (Baker et al., 2003), indicates that it is 
reasonable to postulate involvement of nonvesicular glutamate in 
other disorders involving abnormal glutamate signaling. 
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